Liver Cancer (HCC) Treatment Denied by Insurance: How to Appeal

Hepatocellular carcinoma (HCC) is the most common primary liver cancer in the United States and one of the leading causes of cancer death globally. It typically develops in the setting of cirrhosis from hepatitis B, hepatitis C, or alcohol-related liver disease. The treatment landscape for HCC has evolved significantly, with atezolizumab + bevacizumab now replacing sorafenib as the preferred first-line therapy for advanced disease. Locoregional therapies including transarterial chemoembolization (TACE) and ablation remain standard for intermediate-stage disease. Liver transplantation can be curative for selected patients. Insurance denials across all of these modalities are common and frequently reversible.

Common HCC Denial Scenarios

Sorafenib (Nexavar) and Lenvatinib (Lenvima)

Sorafenib was the first FDA-approved systemic therapy for advanced HCC and remains an NCCN-listed option. Lenvatinib is non-inferior to sorafenib as first-line therapy for advanced HCC based on the REFLECT trial. Insurers may deny these agents by:

• Applying step therapy requiring sorafenib failure before approving lenvatinib
• Denying lenvatinib as "investigational" despite FDA approval
• Restricting dosing schedules that don't match narrow label interpretations

Atezolizumab + Bevacizumab (Tecentriq + Avastin)

The combination of atezolizumab and bevacizumab is now the preferred first-line regimen for patients with unresectable or metastatic HCC who are Child-Pugh class A with ECOG PS 0-1, based on the IMbrave150 trial showing superior overall and progression-free survival versus sorafenib. Insurers deny this combination by:

• Requiring sorafenib as step therapy before approving atezolizumab + bevacizumab, despite it being FDA-approved and NCCN preferred first-line
• Denying bevacizumab as a separate biologic requiring its own Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization
• Applying esophageal varices screening requirements (clinically appropriate but sometimes used as an administrative delay tactic)

Nivolumab, Pembrolizumab, Regorafenib, Cabozantinib, Ramucirumab

Multiple second-line agents are FDA-approved for HCC: nivolumab (with or without ipilimumab), pembrolizumab, regorafenib (for sorafenib-tolerant patients), cabozantinib, and ramucirumab (for AFP ≥ 400 ng/mL). Insurers deny second-line therapies by applying rigid step therapy sequences that don't align with individual patient circumstances.

Transarterial Chemoembolization (TACE)

TACE is the standard locoregional therapy for intermediate-stage HCC (BCLC B — multinodular, preserved liver function, no vascular invasion). Drug-eluting bead TACE (DEB-TACE) and conventional TACE are both used. Insurers may deny:

• TACE as "experimental" or "investigational" despite decades of evidence and NCCN Category 1 listing
• Repeat TACE sessions when clinical benefit is documented (partial response, stable disease)
• TACE in combination with systemic therapy (investigational use, separate discussion)

Thermal Ablation (RFA, MWA)

Radiofrequency ablation (RFA) and microwave ablation (MWA) are standard treatments for small HCCs (≤ 3 cm) that are not candidates for resection or as bridge therapy to transplant. Insurers may deny ablation by calling it "experimental" or requiring surgical resection first.

Liver Transplantation for HCC

Liver transplantation is potentially curative for HCC meeting Milan criteria (1 tumor ≤ 5 cm, or 3 tumors each ≤ 3 cm, no vascular invasion, no extrahepatic spread). Patients within extended criteria (UCSF, Up-to-7) may also be considered at experienced centers. Insurers may deny:

• Transplant evaluation authorization for HCC patients within accepted criteria
• Locoregional therapy as bridge-to-transplant (essential to keep patients within criteria while waiting)
• Organ procurement costs and donor evaluation expenses
• Post-transplant immunosuppression coverage

Cirrhosis and Child-Pugh Class

Many HCC patients have underlying cirrhosis with impaired liver function. Child-Pugh class and MELD score affect treatment eligibility and may be used by insurers to deny certain therapies. However, Child-Pugh class A patients — who have preserved liver function — are eligible for the full range of approved systemic therapies, and denials citing "liver dysfunction" for Child-Pugh A patients are not clinically supported.

Your Legal Rights

ACA essential health benefits: HCC treatment is covered under cancer treatment EHB with no lifetime or annual dollar limits.

External Independent Review: Complete Guide" class="auto-link">External review: For TACE, transplant, and systemic therapy denials, independent external reviewers with hepatology or oncology expertise regularly reverse insurer decisions.

Expedited review: For rapidly progressing HCC or patients near the edge of transplant eligibility criteria, expedited 72-hour review is clinically appropriate.

Building Your Appeal

1. Imaging report: Multiphasic CT or MRI confirming HCC diagnosis and BCLC staging
2. Child-Pugh class assessment and MELD score: Documenting liver function status
3. NCCN Hepatobiliary Cancers Guidelines: Cite specific treatment recommendations by BCLC stage
4. IMbrave150 trial publication: For atezolizumab + bevacizumab first-line appeals
5. Letter of medical necessity: From the treating hepatologist or GI oncologist, ideally at a transplant center if transplant is involved
6. AFP level documentation: Relevant for ramucirumab and transplant eligibility

Fight Back With ClaimBack

ClaimBack helps HCC patients appeal insurance denials for locoregional therapy, systemic treatment, and liver transplant authorization. The evidence for these treatments is strong, and the right appeal can make the difference.

Start your appeal at ClaimBack

Liver cancer insurance denials are common but frequently overturned. Take action and protect your access to evidence-based care.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeals